Building the world’s largest atlas of engineered protein interaction data. DeepSeq’s Function-First platform maps live-cell PPI physics to engineer drugs that go beyond simple binder prediction.
Investors 2
| Date | Name | Website |
| 13.04.2024 | Berkeley S... | skydeck.be... |
| - | Merck Digi... | mds.studio |
Mentions in press and media 3
| Date | Title | Description |
| 20.04.2026 | DeepSeq.AI Announces Presentation at SynBioBeta Conference on May 5, 2026 | Transforming AI-Based Protein Drug Discovery Using HyperScaled Data DeepSeq.AI is driving a paradigm shift from "Structure-First" to "Function-First" by training protein language models on billions to trillions of experi... |
| 16.02.2026 | ZAKA VC Backs DeepSeq.AI’s Functional Approach to Protein Drug Discovery | ZAKA VC backs DeepSeq.AI’s hyperscaled functional data application for AI-driven protein drug discovery The founding team combines AI innovation, biological screening, and commercial biotech leadership The platform focuses on function, not ... |
| 07.01.2026 | Zaka VC Invests in DeepSeq.AI to Transform AI-Based Protein Drug Discovery | Transforming AI-Based Protein Drug Discovery Using HyperScaled Data The team brings a strong balance of scientific and commercial expertise, has built a unique data foundation with a compelling moat, and has already demonstrated promising e... |